Dotatate
- Generic Name
- Dotatate
- Drug Type
- Small Molecule
- Chemical Formula
- C65H90N14O19S2
- CAS Number
- 177943-88-3
- Unique Ingredient Identifier
- MRL3739G66
Radiopharmaceuticals Reshape Cancer Treatment Landscape: From Thyroid to Advanced Prostate Cancer
• Radiopharmaceuticals have evolved from pioneering thyroid cancer treatments to cutting-edge therapies like Lutathera for neuroendocrine tumors and Pluvicto for PSMA-positive prostate cancer.
• Supply chain challenges and short half-lives of radiopharmaceuticals necessitate careful coordination between radiopharmacists, oncologists, and nuclear medicine specialists for timely delivery and administration.
• Emerging developments include Actinium-225 for treatment-resistant cancers and new targeted therapies for lung, breast, and colorectal cancers, with approximately 60-70 startups conducting clinical trials.
Peptide Therapeutics Show Promise in Targeted Cancer Treatment and Diagnosis
• Peptide-based diagnostics, like gallium-68 DOTATATE, enhance cancer imaging and detection with greater sensitivity and specificity, enabling earlier and more precise disease monitoring.
• Peptide drugs, such as Lutathera, combine somatostatin analogs with radioactive isotopes for targeted radiation therapy, while peptide vaccines activate the immune system to combat cancer cells.
• Innovations in peptide engineering and delivery mechanisms, including cyclization techniques and cell-penetrating peptides, are improving peptide stability, bioavailability, and targeted delivery to cancer cells.
• Personalized medicine approaches using peptides are emerging, customizing treatments to individual cancer profiles, offering the potential for more effective, less harmful, and individualized cancer care.
Ariceum Therapeutics Presents Promising Data on 225Ac-Satoreotide at EANM 2024
Ariceum Therapeutics showcased significant findings on 225Ac-Satoreotide, a novel radiopharmaceutical, at the European Association of Nuclear Medicine 2024 conference. The drug demonstrated superior anti-tumour efficacy and pharmacokinetic profile compared to DOTA-TATE, marking a potential breakthrough in treating SSTR2-positive cancers.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath